Lung cancer
Conditions
Interventions
Gold Standard:1. Pathological diagnosis of lung cancer
2. Amplification refractory mutation system.
Sponsors
Fujian Province Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Histologically identified lung adenocarcinoma; 2. Aged 18 to 75 years old, life expectancy = 12 weeks; 3. According to TNM staging (IASLC 2009 version) identified as IV period; 4. No chemotherapy, targeting, biological or immunotherapy. The duration of prior radical surgery or radical radiotherapy must be more than 6 months from the first day of treatment, allowing adjuvant chemotherapy after radical surgery, but more than 6 months from the first day of treatment; 5. Measurable lesions according to RECIST 1.1 standard; 6. WHO physical status score (PS) 0-2 level; 7. Able to comply with research requirements and follow-up procedures, signed informed consent; 8. The total bilirubin (TB) = 1.5×10^9/L, (ALT) and aspartate aminotransferase (AST) = 2 times the normal upper limit; for liver metastases, ALT and AST = 5 times the normal upper limit, creatinine clearance = 50ml/min.;Inclusion criteria: 1. Histologically identified lung adenocarcinoma; 2. Aged 18 to 75 years old, life expectancy = 12 weeks; 3. According to TNM staging (IASLC 2009 version) identified as IV period; 4. No chemotherapy, targeting, biological or immunotherapy. The duration of prior radical surgery or radical radiotherapy must be more than 6 months from the first day of treatment, allowing adjuvant chemotherapy after radical surgery, but more than 6 months from the first day of treatment; 5. Measurable lesions according to RECIST 1.1 standard; 6. WHO physical status score (PS) 0-2 level; 7. Able to comply with research requirements and follow-up procedures, signed informed consent; 8. The total bilirubin (TB) = 1.5×10^9/L, (ALT) and aspartate aminotransferase (AST) = 2 times the normal upper limit; for liver metastases, ALT and AST = 5 times the normal upper limit, creatinine clearance = 50ml/min.;Inclusion criteria: 1. Histologically identified lung adenocarcinoma; 2. Aged 18 to 75 years old, life expectancy = 12 weeks; 3. According to TNM staging (IASLC 2009 version) identified as IV period; 4. No chemotherapy, targeting, biological or immunotherapy. The duration of prior radical surgery or radical radiotherapy must be more than 6 months from the first day of treatment, allowing adjuvant chemotherapy after radical surgery, but more than 6 months from the first day of treatment; 5. Measurable lesions according to RECIST 1.1 standard; 6. WHO physical status score (PS) 0-2 level; 7. Able to comply with research requirements and follow-up procedures, signed informed consent; 8. The total bilirubin (TB) = 1.5×10^9/L, (ALT) and aspartate aminotransferase (AST) = 2 times the normal upper limit; for liver metastases, ALT and AST = 5 times the normal upper limit, creatinine clearance = 50ml/min.;Inclusion criteria: 1. Histologically identified lung adenocarcinoma; 2. Aged 18 to 75 years old, life expectancy = 12 weeks; 3. According to TNM staging (IASLC 2009 version) identified as IV period; 4. No chemotherapy, targeting, biological or immunotherapy. The duration of prior radical surgery or radical radiotherapy must be more than 6 months from the first day of treatment, allowing adjuvant chemotherapy after radical surgery, but more than 6 months from the first day of treatment; 5. Measurable lesions according to RECIST 1.1 standard; 6. WHO physical status score (PS) 0-2 level; 7. Able to comply with research requirements and follow-up procedures, signed informed consent; 8. The total bilirubin (TB) = 1.5×10^9/L, (ALT) and aspartate aminotransferase (AST) = 2 times the normal upper limit; for liver metastases, ALT and AST = 5 times the normal upper limit, creatinine clearance = 50ml/min.;Inclusion criteria: 1. Histologically identified lung adenocarcinoma; 2. Aged 18 to 75 years old, life expectancy = 12 weeks; 3. According to TNM staging (IASLC 2009 version) identified as IV period; 4. No chemotherapy, targeting, biological or immunotherapy. The duration of prior radical surgery or radical radiotherapy must be more than 6 months from the first day of treatment, allowing adjuvant chemotherapy after radical surgery, but more than 6 months from the first day of treatment; 5. Measurable lesions according to RECIST 1.1 standard; 6. WHO physical status score (PS) 0-2 level; 7. Able to comply with research requirements and follow-up procedures, signed informed consent; 8. The total bilirubin (TB) = 1.5×10^9/L, (ALT) and aspartate aminotransferase (AST) = 2 times the normal upper limit; for liver metastases, ALT and AST = 5 times the normal upper limit, creatinine clearance = 50ml/min.
Exclusion criteria
Exclusion criteria: 1. Serious violation of the criteria for inclusion in the case; 2. no test records available for evaluation; 3. the loss of patients during follow-up; 4. independent of the disease changes or death occurred during treatment and follow-up which lead to can not continue to observe.;Exclusion criteria: 1. Serious violation of the criteria for inclusion in the case; 2. no test records available for evaluation; 3. the loss of patients during follow-up; 4. independent of the disease changes or death occurred during treatment and follow-up which lead to can not continue to observe.;Exclusion criteria: 1. Serious violation of the criteria for inclusion in the case; 2. no test records available for evaluation; 3. the loss of patients during follow-up; 4. independent of the disease changes or death occurred during treatment and follow-up which lead to can not continue to observe.;Exclusion criteria: 1. Serious violation of the criteria for inclusion in the case; 2. no test records available for evaluation; 3. the loss of patients during follow-up; 4. independent of the disease changes or death occurred during treatment and follow-up which lead to can not continue to observe.;Exclusion criteria: 1. Serious violation of the criteria for inclusion in the case; 2. no test records available for evaluation; 3. the loss of patients during follow-up; 4. independent of the disease changes or death occurred during treatment and follow-up which lead to can not continue to observe.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EGFR Gene Mutation Phenotype;EGFR Gene Mutation Phenotype;Accuracy;Sensitivity;Specificity;Positive predictive value;Negative predictive value;Objective remission rate;No progression-free survival;overall survival; | — |
Countries
China
Contacts
Public ContactZhuang Wu;Zhuang Wu;Zhuang Wu;Zhuang Wu;Zhuang Wu ;;;;
Fujian Province Cancer Hospital;Fujian Province Cancer Hospital;Fujian Province Cancer Hospital;Fujian Province Cancer Hospital;Fujian Province Cancer Hospital
Outcome results
None listed